on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has reported its position regarding shares in Avadel Pharmaceuticals plc. The disclosure aligns with the requirements of the Irish Takeover Panel Act, 1997. Per the filing dated 16 January 2026, Vanguard holds 5,855,442 ordinary shares in Avadel, representing a 6.01% stake in the company.
The disclosure, made under Rule 8.3, does not indicate any additional parties involved in dealings. Additionally, the report reveals a purchase of 3,423 shares at a price of 21.48 USD per share. No cash-settled or stock-settled derivative positions are currently reported.
Vanguard states no existing indemnities, options, or formal agreements concerning these securities. There are no supplemental forms attached, reinforcing the straightforward nature of its stake disclosure. These filings ensure transparency in Vanguard's investment activities with respect to Avadel Pharmaceuticals.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news